

Contents

Preface	V
List of Contributors	IX
1 Rational Design of Bioactive Molecules	
<i>K. Gubernator and H. J. Böhm</i>	1
1.1 Introduction	1
1.1.1 From Ligand Design to Drug Discovery	1
1.2 Source of Structural Information	2
1.3 Classes of Therapeutic Agents	3
1.4 Protein–Ligand Interaction	4
1.4.1 Covalent versus Noncovalent Inhibitors	4
1.4.2 Nonbonded Interactions in Protein–Ligand Complexes	4
1.4.3 Hydrogen Bonds	5
1.4.4 The Role of Solvent in Polar Protein–Ligand Interactions	5
1.4.5 Lipophilic Interactions	7
1.4.6 Criteria for Strong Protein–Ligand Interactions	7
1.5 Approaches to Structure-Based Ligand Design	8
1.5.1 Ligands Derived from Substrate or Natural Ligand	8
1.5.2 Structures Derived from 3D Database Searches	9
1.5.3 <i>De Novo</i> Design of Ligands	9
1.6 Methods and Tools used in Structure-Based Ligand Design	9
1.7 Outlook and Future Developments	10
References	11
2 Examples of Active Areas of Structure-Based Design	
<i>K. Gubernator and H. J. Böhm</i>	15
2.1 Thrombin Inhibitors	15
2.2 Design of Orally Active Inhibitors of Elastase	19
2.3 Dorzolamide: A Success Story of Structure-Based Drug Design	23
2.4 Inhibitors of Serine Esterases	26
2.4.1 Human Pancreatic Lipase (hPL)	26
2.4.2 Model of the Trilaurin Triglyceride Substrate Binding	27

2.4.3	Tetrahydropipstatin (THL)	28
2.5	Acetylcholinesterase (AChE)	30
2.5.1	Model of the Acetylcholine Substrate Binding	31
2.5.2	Physostigmine	31
2.5.3	Eisai E2020	34
	References	35
3	From Renin to HIV-1 Protease	
	<i>E. A. Lunney and C. Humblet</i>	37
3.1	Introduction	37
3.2	Renin	38
3.2.1	Catalytic Site Binding	41
3.2.2	Backbone Variations	41
3.2.3	Subsite Interdependencies	44
3.2.4	Renin Crystal Structure	50
3.2.5	Summary – Renin Modeling	51
3.3	HIV-1 Protease	51
3.3.1	3D Structures of HIV-1 Protease	52
3.3.2	HIV-1 Protease Nonpeptide Inhibitors	55
3.3.3	Docking/Modeling HIV-1 Protease Nonpeptide Inhibitors	59
3.4	Summary: Comparison of HIV-1 Protease versus Renin Structure-Based Design	66
3.5	Current Limitations/Future Perspective	67
3.6	Conclusion	68
	References	69
4	Zinc Endoproteases: A Structural Superfamily	
	<i>N. Borkakoti</i>	73
4.1	Introduction	73
4.2	Structural Classification of Zinc Endopeptidase Families	74
4.2.1	Short Spacer or Metzincins Family	74
4.2.2	Long Spacer or Gluzincins Family	78
4.3	Overview of Inhibitor Design	80
4.4	Current Limitations	84
4.5	Future Prospects	85
	References	86
5	Structure-Based Design of Potent Beta-Lactamase Inhibitors	
	<i>K. Gubernator, I. Heinze-Krauss, P. Angehrn, R. L. Charnas, C. Hubschwerlen, C. Oefner, M. P. G. Page and F. K. Winkler</i>	89
5.1	Introduction	89
5.2	Structure of <i>Citrobacter freundii</i> Class C Beta-Lactamase	89
5.3	Model of the Mechanism of Action: Cleavage of Penicillin G	90

5.4	Structure of the Complex with Aztreonam	91
5.5	Design of Inhibitors	95
5.6	Kinetics of the Inhibition Reaction	96
5.7	Hydrolysis by Class A Beta-Lactamases	98
5.8	X-Ray Structure of the Complex with a Bridged Monobactam	99
5.9	Structure–Activity Relationship among Bridged Monobactams	100
5.10	Conclusion	102
	References	102
6	Inhibition of Sialidase	
	<i>N. R. Taylor</i>	105
6.1	Introduction	106
6.2	Influenza: Disease and Virus	107
6.3	Structure of Sialidase	108
6.4	Mechanism of Catalysis	109
6.5	Binding of Substrate and Transition State Mimics	110
6.6	Structure-Based Inhibitor Design	113
6.7	Enzyme–Inhibitor Interactions	114
6.8	Inhibitor Potency, Efficacy and Selectivity	116
6.9	Summary	117
	Acknowledgements	118
	References	118
7	Rational Design of Inhibitors of HIV-1 Reverse Transcriptase	
	<i>W. Schäfer</i>	119
7.1	Introduction	119
7.2	Building a Model	123
7.3	Test of the Model	124
7.4	Optimization of Compound 3	124
7.5	Design of a New Inhibitor	125
7.6	Guidelines and Conclusions	126
	References	127
8	New Computational Approaches to Predict Protein–Ligand Interactions	
	<i>H. J. Böhm</i>	129
8.1	Introduction	129
8.2	The Computer program LUDI	132
8.2.1	Basic Methodology	132
8.2.2	Applications of LUDI	136
8.3	Computational Methods to Predict Ligand Binding Affinities	137
8.3.1	A New Scoring Function for Protein–Ligand Complexes	138
8.4	Current Challenges in Computational <i>De Novo</i> Ligand Design	139

8.5	Summary	140
	References	140
9	The Future of Structure-Based Design: A Worthy Precept?	
	<i>H. J. Böhm and K. Gubernator</i>	143
9.1	Introduction	143
9.2	Developments in the Design Process	143
9.3	Screening Systems	145
9.4	Future Prospects	146
	Acknowledgement	147
	References	147
Index		149